Zimmer Floats Divestments To Win European Approval Of Biomet Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Zimmer is negotiating with the European Commission on a strategic divestment strategy that would allow European anti-trust regulators to approve Zimmer’s pending acquisition of Biomet.
You may also be interested in...
Zimmer-Biomet Deal Clears EU Antitrust Review With Three Divestments
Zimmer and Biomet will drop some knee and elbow product lines to satisfy European regulator concerns over its planned $13.35 billion merger.
New Ortho Juggernaut: Zimmer Acquires Biomet For $13.35 Billion
Zimmer has agreed to buy Biomet by the first quarter of 2015, furthering the trend of consolidation in the $45 billion orthopedic device industry. The companies had combined revenues of $7.8 billion in 2013.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.